Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTRANSDERMALGeneric

PROSTEP

NICOTINE

Standard Dose
22MG/24HR
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview PROSTEP is listed in Drugs@FDA under application 019983 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient NICOTINE Form and strength FILM, EXTENDED RELEASE;TRANSDERMAL - 22MG/24HR Sponsor AVEVA Submission history Latest submission status date: 2002-10-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview PROSTEP is listed in Drugs@FDA under application 019983 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NICOTINE Form and strength FILM, EXTENDED RELEASE;TRANSDERMAL - 22MG/24HR Sponsor AVEVA Submission history Latest submission status date: 2002-10-04 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.